Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.93 USD
−583.20 M USD
622.00 K USD
159.52 M
About ImmunityBio, Inc.
Sector
CEO
Richard Adcock
Headquarters
San Diego
Website
Founded
2014
FIGI
BBG007T9DYW9
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Get IBRX now and never look back.You will never see IBRX below 3.5 again. Already retrace at fib .786 and hits 2 support levels on Monthy intervals. This is your last chance before next report date on Nov 15, 2024.
IBRX - Biotech Short Squeeze Candidate - High Risk / High RewardImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product cand
Buy the Dip, Sell the Rip: 100% Profit in 2 Weeks.Immunity Bio (IBRX) could bounce soon.
- The price is touching the trend line that has served as resistance since October 2023.
- The RSI is slowly moving above the moving average.
- The RCI indicator shows a triple bottom with all three trend lines (short, middle, and long).
- On the chart, th
Tow lines has been broken!!!!!!!!!We may see a breakthrough to 7$, NASDAQ:IBRX , FDA Approves ImmunityBio's Bladder Cancer Drug.
Why trading seems to be difficult ??Fianancial market management is the only business ,where investor or a trader can take decision of max loss he /she could bears , while in offline business seems to predict how much max loss we could experience ! because we can build a house then after we could even face will a earth quake and losin
ibrx might ne a 8 dollar stock maybe ill put in a pic later, but with the look of it it seems like a 8 dollar stock
$IBRX A Step Towards Better ImmunotherapyWhile most oncological treatments focus on bombarding the body with toxic materials in hopes of killing cancerous cells, ImmunityBio, Inc. (Nasdaq: IBRX) utilizes immunology in order to find a solution. Its treatments usually focus on catalyzing NK cells, and T cells, which then kill cancerous cells
IBRX - PDUFA - short squeezeThis is not a financial advice!
Upcoming catalyst and block buys recently.
SL under 1.6
Key level: 2.0 must be broken and hold for bullish confirmation.
TP around 5.0
Only 83.44M float
32% Short float
Most info on the chart.
Trade carefully!
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IBRX is 5.57 USD — it has increased by 5.09% in the past 24 hours. Watch ImmunityBio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ImmunityBio, Inc. stocks are traded under the ticker IBRX.
IBRX stock has risen by 6.30% compared to the previous week, the month change is a 59.60% rise, over the last year ImmunityBio, Inc. has showed a 66.27% increase.
We've gathered analysts' opinions on ImmunityBio, Inc. future price: according to them, IBRX price has a max estimate of 30.00 USD and a min estimate of 4.75 USD. Watch IBRX chart and read a more detailed ImmunityBio, Inc. stock forecast: see what analysts think of ImmunityBio, Inc. and suggest that you do with its stocks.
IBRX reached its all-time high on Feb 22, 2021 with the price of 45.42 USD, and its all-time low was 0.93 USD and was reached on Dec 26, 2018. View more price dynamics on IBRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IBRX stock is 8.56% volatile and has beta coefficient of 2.05. Track ImmunityBio, Inc. stock price on the chart and check out the list of the most volatile stocks — is ImmunityBio, Inc. there?
Today ImmunityBio, Inc. has the market capitalization of 3.88 B, it has increased by 33.97% over the last week.
Yes, you can track ImmunityBio, Inc. financials in yearly and quarterly reports right on TradingView.
ImmunityBio, Inc. is going to release the next earnings report on Nov 15, 2024. Keep track of upcoming events with our Earnings Calendar.
IBRX earnings for the last quarter are −0.20 USD per share, whereas the estimation was −0.16 USD resulting in a −25.00% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about ImmunityBio, Inc. earnings.
ImmunityBio, Inc. revenue for the last quarter amounts to 1.05 M USD, despite the estimated figure of 14.71 M USD. In the next quarter, revenue is expected to reach 2.92 M USD.
IBRX net income for the last quarter is −134.56 M USD, while the quarter before that showed −134.11 M USD of net income which accounts for −0.34% change. Track more ImmunityBio, Inc. financial stats to get the full picture.
No, IBRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 628.00 employees. See our rating of the largest employees — is ImmunityBio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ImmunityBio, Inc. EBITDA is −341.06 M USD, and current EBITDA margin is −55.12 K%. See more stats in ImmunityBio, Inc. financial statements.
Like other stocks, IBRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ImmunityBio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ImmunityBio, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ImmunityBio, Inc. stock shows the buy signal. See more of ImmunityBio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.